1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
FamiCord AG

FamiCord AG

VTIAF
FamiCord AGUS flagOther OTC
6.38
USD
- -
- -
111.13MMarket Cap
FamiCord AG
VTIAF
(Other OTC)

Recent

price

6.38

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.23
5.88
4.66
4.35
4.42
4.66
5.34
5.41
5
4.86
4.8
4.88
4.36
4.85
4.71
- -
3.64
Revenue per Share
0.13
0.46
-0.2
0.27
0.35
0.65
0.13
-0.09
0.2
0.18
0.35
-0.63
-1.71
-0.12
-0.7
- -
0.09
Basic EPS, GAAP
0.01
-0.62
0.37
0.33
0.2
0.65
0.6
0.22
0.93
1.33
0.7
0.08
-0.69
0.32
0.31
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.15
0.16
0.13
0.16
0.16
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.97
0.97
1.04
0.97
0.97
1
1.93
1.68
1.47
0.3
0.66
1.87
-0.92
-0.86
-1.41
- -
-1.72
Book Value per Share
-0.6
-0.02
-0.32
0.06
0.49
-0.8
-0.47
-2.91
-2.15
-2.36
-1.54
-5.93
-2.67
-2.05
-1.8
- -
-2.29
Tangible Book Value per Share
3
3
3
3
3
3
3
4
4
4
4
6
16
16
17
- -
18
Basic Weighted Avg Shares
17
16
14
14
14
14
16
19
20
20
20
28
69
77
82
88
66
Sales/Revenue/Turnover
4.38
-2.09
-5.45
10.84
10.53
-10.57
4.76
0.7
12.89
12.29
10.04
0.82
-36.06
-3.22
-10.95
-2.72
2.87
Operating Margin (%)
1
1
1
1
1
2
2
2
2
3
3
4
9
9
9
8
6
Depreciation Expense
- -
1
-1
1
1
2
- -
- -
1
1
1
-4
-27
-2
-12
-6
2
Net Income, GAAP
47.6
- -
- -
41.33
41.66
- -
10.33
- -
53.36
68.96
22.72
- -
- -
- -
- -
- -
13.7
Effective Tax Rate (%)
2.06
7.89
-4.26
6.18
7.98
13.97
2.5
-1.68
4.06
3.72
7.37
-12.9
-39.29
-2.42
-14.77
-7.15
2.48
Profit Margin (%)
3
3
3
4
6
2
3
1
4
4
6
-8
-27
-14
-15
-18
-16
Working Capital
2
2
- -
- -
- -
2
- -
7
5
5
3
20
12
14
13
19
20
LT Debt
19
20
20
21
22
24
24
30
30
25
26
42
16
24
13
5
5
Total Equity
1.79
- -
- -
3.89
3.82
- -
2.72
- -
3.29
2.18
4.71
- -
- -
- -
- -
- -
5.38
Return on Invested Capital (%)
6.65
- -
- -
21.59
35.37
- -
3.19
- -
6.06
7.56
19.4
- -
- -
- -
- -
- -
-36.79
Return on Capital (%)
13.18
47.68
-20.41
27.68
36.34
65.38
9.15
-5.45
13.86
20.5
73.57
-53.89
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
8
5
5
LT Borrowings
3
11
13
LT Finance Leases
8
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
78
91
100

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
40
39
41
Cash, Cash Equivalents & STI
13
10
14
Accounts Receivable, Net
16
16
16
Inventories
3
3
3
Total Current Liabilities
58
58
58
Payables & Accruals
- -
- -
- -
ST Debt
8
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.16%
-11.15%
-58.04%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
16.51%
139.03%
-48.06%
Sales/Revenue/Turnover
24.82%
42.56%
7.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19
19
22
22
82
2025
22
21
23
- -
88
2026
21
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.09
0.08
- -
-0.7
2025
-0.04
0.04
0.07
- -
- -
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
MedPacto, Inc. (235980.KQ)
Aditxt, Inc. (ADTX)
AlphaTON Capital Corp. (ATON)
TCR2 Therapeutics Inc. (TCRR)
Oncopeptides AB (publ) (ONCO.ST)
RenovaCare, Inc. (RCAR)
Business
FamiCord AG FamiCord AG (formerly Vita 34 AG) operates as Europe's largest and the world's third-largest stem cell bank, specializing in the collection, processing, cryopreservation, and long-term storage of stem cells from umbilical cord blood, umbilical cord tissue, placenta tissue, and other postnatal tissues; it provides full-service biobanking solutions including logistics, testing, and release for clinical applications, alongside contract development and manufacturing organization (CDMO) services for cell and gene therapies, advanced therapy medicinal products (ATMPs), viral vectors, CAR-T cells, genetic tests, and analyses for third-party biotech firms, clinics, and research institutions. The company serves families and healthcare providers across approximately 50 countries, with key markets in Germany, Poland, Switzerland, Romania, Turkey, the GCC region, Italy, and operations extending to Europe, Asia, and Africa through an extensive network of over 1,500 partner clinics; it has preserved over one million units of biological material and facilitated stem cells for more than 7,000 patient treatments, including over 230 cord blood transplantations. Founded in 1997 and headquartered in Leipzig, Germany, FamiCord AG employs around 766 people and reports segmental revenues primarily from its Vita 34 and PBKM subgroups. In recent developments, FamiCord AG changed its name from Vita 34 AG in February 2025 to reflect the integration of its Vita 34 and PBKM subgroups following their merger; the company completed the acquisition of Seracell Pharma AG, enhancing its stem cell therapy development and ATMP manufacturing capabilities, and acquired BioCell Lugano in Switzerland to expand laboratory infrastructure. Its subsidiary PBKM agreed to acquire 100% of nOvum stem cell bank in Poland in September 2025, while FamiCord AG took a majority stake in Národní Centrum Pupečníkové Krve and Rodinná banka perinatálnych a mezenchymálnych buniek in May 2025 to bolster its Central European presence. Additionally, it rolled out placenta banking services across markets including Switzerland, Poland, Romania, GCC, and Italy, with full expansion targeted by end-2026, and appointed Tomasz Baran as Chief Medical Officer in April 2025 to advance stem cell therapy collaborations with universities and institutions.

Company News

APIChatGPT